Literature DB >> 12359741

A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma.

Remco van Doorn1, Remco Dijkman, Maarten H Vermeer, Theo M Starink, Rein Willemze, Cornelis P Tensen.   

Abstract

Defective apoptosis signaling has been implicated in the pathogenesis of primary cutaneous T-cell lymphomas (CTCLs), a group of malignancies derived from skin-homing T cells. An important mediator of apoptosis in T cells is the Fas receptor. We identified a novel splice variant of the Fas gene that displays retention of intron 5 and encodes a dysfunctional Fas protein in 13 of 22 patients (59%) in both early and advanced CTCL. Impairment of Fas-induced apoptosis resulting from aberrant splicing potentially contributes to the development and progression of CTCL by allowing continued clonal expansion of activated T cells and by reducing susceptibility to antitumor immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359741

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

Authors:  Jianqiang Wu; Jawed Siddiqui; Minakshi Nihal; Eric C Vonderheid; Gary S Wood
Journal:  Arch Biochem Biophys       Date:  2010-10-29       Impact factor: 4.013

2.  Clinical relevance of Fas expression in oesophageal squamous cell carcinoma.

Authors:  K W Chan; P Y Lee; A K Y Lam; S Law; J Wong; G Srivastava
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

3.  Interleukin-16 as a marker of Sézary syndrome onset and stage.

Authors:  Jillian Richmond; Marina Tuzova; Ashley Parks; Natalie Adams; Elizabeth Martin; Marianne Tawa; Lynne Morrison; Keri Chaney; Thomas S Kupper; Clara Curiel-Lewandrowski; William Cruikshank
Journal:  J Clin Immunol       Date:  2010-09-28       Impact factor: 8.317

Review 4.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

5.  Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70.

Authors:  K Ferenczi; J Ohtola; P Aubert; M Kessler; H Sugiyama; A K Somani; A C Gilliam; J Z Chen; I Yeh; S Matsuyama; T S McCormick; K D Cooper
Journal:  Br J Dermatol       Date:  2010-09       Impact factor: 9.302

6.  BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.

Authors:  S Esmailzadeh; Y Huang; M-W Su; Y Zhou; X Jiang
Journal:  Leukemia       Date:  2015-01-12       Impact factor: 11.528

7.  Over-expressed Fas improves the apoptosis of malignant T-cells in vitro and vivo.

Authors:  Linghao Li; Ri Zhang; Zixing Chen; Shengli Xue; Xiuli Wang; Changgeng Ruan
Journal:  Mol Biol Rep       Date:  2011-03-11       Impact factor: 2.316

8.  Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis.

Authors:  Shulamit B Wallach-Dayan; Regina Golan-Gerstl; Raphael Breuer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

Review 9.  Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.

Authors:  William E Damsky; Jaehyuk Choi
Journal:  Curr Treat Options Oncol       Date:  2016-07

Review 10.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.

Authors:  Joseph S Durgin; David M Weiner; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.